Oxford BioDynamics

The company, which went public in 2017, generates all its revenues through its epigenetic biomarker research and development partnerships.

Oxford BioDynamics will work with Italian research institute Casa Sollievo della Sofferenza to identify blood-based biomarkers of autism spectrum disorder.

Participants aim to use predictive modeling to better understand epigenetic mechanisms, while encouraging the development of new technologies and therapies.

Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.

The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.

The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions.

The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.

Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.